These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 35657119)

  • 1. A comparative review on mucocutaneous reactions caused by Covid-19 infection versus Covid-19 vaccination.
    Sadeghi S; Amini Z; Goodarzi A
    Exp Dermatol; 2022 Aug; 31(8):1122-1127. PubMed ID: 35657119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.
    Seirafianpour F; Pourriyahi H; Gholizadeh Mesgarha M; Pour Mohammad A; Shaka Z; Goodarzi A
    Dermatol Ther; 2022 Jun; 35(6):e15461. PubMed ID: 35316551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: A systematic review and meta-analysis.
    Washrawirul C; Triwatcharikorn J; Phannajit J; Ullman M; Susantitaphong P; Rerknimitr P
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):1947-1968. PubMed ID: 35666609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers.
    Maruyama A; Sawa T; Teramukai S; Katoh N
    J Infect Chemother; 2022 Jul; 28(7):934-942. PubMed ID: 35361536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical and pathologic spectrum of mucocutaneous reactions after COVID-19 vaccinations in three tertiary referral centers of northern Italy.
    Paolino G; Caputo V; Schroeder J; Marzano AV; Bonoldi E; Moltrasio C; Maronese CA; Borgonovo L; Rongioletti F
    Clin Dermatol; 2023; 41(2):312-319. PubMed ID: 36863621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety Monitoring after the BNT162b2 COVID-19 Vaccine among Adults Aged 75 Years or Older.
    Choi YY; Kim MK; Kwon HC; Kim GH
    J Korean Med Sci; 2021 Nov; 36(45):e318. PubMed ID: 34811980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous adverse reactions of COVID-19 vaccines: A systematic review.
    Qaderi K; Golezar MH; Mardani A; Mallah MA; Moradi B; Kavoussi H; Shamsabadi A; Golezar S
    Dermatol Ther; 2022 May; 35(5):e15391. PubMed ID: 35194894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An extremely rare mucocutaneous adverse reaction following COVID-19 vaccination: Toxic epidermal necrolysis.
    Mardani M; Mardani S; Asadi Kani Z; Hakamifard A
    Dermatol Ther; 2022 May; 35(5):e15416. PubMed ID: 35238119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis.
    Guo Y; Cao XS; Yang HT; Zhou MG; Yu B
    J Glob Health; 2023 Feb; 13():06008. PubMed ID: 36757823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records.
    Niesen MJM; Pawlowski C; O'Horo JC; Challener DW; Silvert E; Donadio G; Lenehan PJ; Virk A; Swift MD; Speicher LL; Gordon JE; Geyer HL; Halamka JD; Venkatakrishnan AJ; Soundararajan V; Badley AD
    JAMA Netw Open; 2022 Apr; 5(4):e227038. PubMed ID: 35420661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Systematic Review of Histopathologic Surveys on Mucocutaneous Biopsies in Patients Developed COVID-19 Vaccine-Related Dermatologic Manifestations.
    Salehi S; Sadeghi S; Kalantari Y; Goodarzi A
    Am J Dermatopathol; 2023 Jan; 45(1):1-27. PubMed ID: 36484603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
    PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.
    Rosenblum HG; Gee J; Liu R; Marquez PL; Zhang B; Strid P; Abara WE; McNeil MM; Myers TR; Hause AM; Su JR; Markowitz LE; Shimabukuro TT; Shay DK
    Lancet Infect Dis; 2022 Jun; 22(6):802-812. PubMed ID: 35271805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.
    Meo SA; Shaikh N; Abukhalaf FA; Meo AS
    Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study.
    Grieco T; Maddalena P; Sernicola A; Muharremi R; Basili S; Alvaro D; Cangemi R; Rossi A; Pellacani G
    Dermatol Ther; 2021 Nov; 34(6):e15153. PubMed ID: 34622531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side effects after COVID-19 vaccinations among residents of Poland.
    Andrzejczak-Grządko S; Czudy Z; Donderska M
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(12):4418-4421. PubMed ID: 34227078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucocutaneous Adverse Reactions to COVID-19 Vaccines: Do Excipients Play a Role?
    Bianchi L; Biondi F; Hansel K; Murgia N; D'Arpino A; Tramontana M; Stingeni L
    Acta Derm Venereol; 2022 May; 102():adv00724. PubMed ID: 35535644
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.